These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9915232)

  • 1. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.
    Dudek MM; Harris LF; Killard AJ
    Int J Lab Hematol; 2011 Jun; 33(3):272-80. PubMed ID: 21118388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.
    Scialla SJ
    Am J Clin Pathol; 1985 Sep; 84(3):351-4. PubMed ID: 4036867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
    Francis JL; Howard C
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental quality assessment of APTT-control reagent kits in the study of heparin-containing plasma in therapeutic ranges].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 Apr; (4):39-41. PubMed ID: 21735680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions.
    Poller L; Thomson JM; Taberner DA
    Ric Clin Lab; 1989; 19(4):363-70. PubMed ID: 2633304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing different lots of activated partial thromboplastin time reagent: analysis of two methods.
    Rosborough TK
    Am J Clin Pathol; 1998 Aug; 110(2):173-7. PubMed ID: 9704615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring the efficiency of heparin anticoagulation in patients on programmed hemodialysis].
    Berkovskiĭ AL; Sergeeva EV; Suvorov AV; Mondoev LG; Kabardina MS; Biriukova LS; Kozlov AA
    Klin Lab Diagn; 2010 Dec; (12):30-2. PubMed ID: 21395052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges.
    van den Besselaar AM; Sturk A; Reijnierse GL
    Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
    Francis JL; Hursting MJ
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant.
    Adcock DM; Marlar RA
    Arch Pathol Lab Med; 1992 Aug; 116(8):837-40. PubMed ID: 1497465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.